GlassScriptPhysician profile
Nam H Kim
NPI 1154424364
$11,993.18
in general payments reported to CMS, 2019-2025
14 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $1,144 · 2021: $2,425 · 2022: $2,706 · 2023: $1,805 · 2024: $1,220 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,307.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $8,576.09 | 2021-2025 | Azure Xt Dr Mri Surescan, Crome Dr Mri Surescan, Micra |
| Medtronic Vascular, INC. | $1,791.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $939.03 | 2019-2024 | Farxiga |
| Abiomed | $182.57 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.72 | 2021 | |
| Ge Healthcare | $38.74 | 2023 | |
| Boston Scientific Corporation | $38.65 | 2025 | Flextome Cutting Balloon |
| Stryker Corporation | $38.11 | 2025 | Artix Mt |
| Merck Sharp & Dohme LLC | $35.87 | 2022-2024 | Bridion |
| Pfizer INC. | $27.73 | 2021 | |
| Innovation Technologies INC | $24.15 | 2023 | Irrisept |
| Silk Road Medical, INC. | $18.94 | 2020 | |
| Chiesi USA, INC. | $11.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nam Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.